Comment on: clinical value of circulating tumor DNA for patients with epithelial ovarian cancer

Authors

Abstract

PRP and exosome-based therapies may carry a theoretical risk of contamination with circulating tumor DNA (ctDNA) and tumor cells, and their long-term oncological safety remains unclear, particularly in patients with a history of cancer.

Letter to the EditorThe purpose of this letter is to highlight the potential clinical implications and importance of circulating tumor cells and DNA in oncology patients undergoing PRP (Platelet-Rich Plasma). The presence of circulating tumor DNA (ctDNA) and tumor cells can be a marker of disease progression and minimal residual disease in solid tumors, similar to hematological malignancies [1].
In recent years, the use of PRP and exosome-based therapies in cosmetic and regenerative medicine has increased. While these products are derived from patients’ own blood and subjected to centrifugation and purification, the theoretical risk of contamination with tumor-derived material from existing or past malignancies remains [2]. Some studies have shown that these biologics may not have adverse effects in the short term; however, the long-term oncological safety of such treat- ments remains uncertain and requires further evaluation [3].
Additionally, many researchers are considering the potential role of circulating tumor DNA and PRP-derived components in cancer treatment monitoring and per- sonalized oncology therapy [4]. However, until sufficient long-term evidence is available, it would be prudent to avoid such biologic/cosmetic interventions or plan individualized treatment for patients with a history of cancer.

References

1. Laude É, Azaïs H, Ben Sassi M, Bats AS, Taly V, Laurent-Puig P. Clinical value of circulating tumor DNA for patients with epithelial ovarian cancer. Int J Gynecol Cancer. 2025;35(7):101925. doi:10.1016/j.ijgc.2025.101925
   Article PubMed Google Scholar
2. Han C, Chen C, Lu N, et al. Platelet-rich plasma inhibits breast cancer proliferation. Clin Med Insights Oncol. 2024;18:11795549241298978. doi:10.1177/11795549241298978
   Article PubMed Google Scholar
3. Eichler C, Üner J, Thangarajah F, et al. Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients. Arch Gynecol Obstet. 2022;306(4):1171-1176. doi:10.1007/s00404-022-06416-4
   Article PubMed Google Scholar
4. Luzo ACM, Fávaro WJ, Seabra AB, Durán N. What is the potential use of platelet-rich plasma (PRP) in cancer treatment? A mini review. Heliyon. 2020;6(3):e03660. doi:10.1016/j.heliyon.2020.e03660
   Article PubMed Google Scholar

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →

About This Article